In summary, our data demonstrated that LINC00052 acted as a tumor suppressor by inhibiting malignant progression of human HCC and revealed a novel LINC00052-miR-452-5P-EPB41L3 regulatory network in HCC. Here, EPB41L3 is linked to neoplasm.